for people ages 12 years and up (full criteria)
at San Francisco, California and other locations
study started
completion around



This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with an approved medication called pembrolizumab.

The objective of this study is to see if the combination of fianlimab and cemiplimab is an effective treatment compared to pembrolizumab in patients that have had melanoma removal surgery but are still at high risk for the recurrence of the disease. Pembrolizumab is an approved treatment in some countries in this clinical setting.

The study is looking at several other research questions, including:

  • What side effects may happen from receiving the study drugs.
  • How much study drug is in the blood at different times.
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects). Antibodies are proteins that are naturally found in the blood stream that fight infections.
  • How administering the study drugs might improve quality of life.

Official Title

A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma


Melanoma, Resected High Risk Melanoma, Skin Cancer, Stage IIB, Stage IIC, Stage III, Stage IV, LAG-3 Lymphocyte activation gene 3, Adjuvant Setting, anti-PD-1 Monoclonal Antibody, Pembrolizumab, Cemiplimab, Fianlimab, Fianlimab HD + Cemiplimab, Fianlimab LD + Cemiplimab


You can join if…

Open to people ages 12 years and up

  1. All patients must be either stage IIB, IIC, III, or stage IV per American Joint Committee on Cancer (AJCC) 8th edition and have histologically confirmed melanoma that is completely surgically resected in order to be eligible as defined by the protocol
  2. Complete surgical resection must be performed within 12 weeks prior to randomization, and enrollment may occur only after satisfactory wound healing from the surgery
  3. All patients must have disease-free status documented by a complete physical examination and imaging studies within 4 weeks prior to randomization, as described in the protocol

You CAN'T join if...

  1. Uveal melanoma
  2. Any evidence of residual disease after surgery by imaging, pathology, or cytology.
  3. Ongoing or recent (within 2 years) evidence of clinically significant autoimmune disease that required treatment
  4. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C (HCV) infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection, as described in the protocol
  5. Another malignancy that is currently progressing or that required active treatment in the past 5 years, as described in the protocol
  6. Participants with a history of myocarditis
  7. Adolescent patients (≥12 to <18 years old) with body weight <40 kg

Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply


  • UCSF accepting new patients
    San Francisco California 94158-3214 United States
  • John Wayne Cancer Institute - Saint John's Health Center accepting new patients
    Santa Monica California 90404-2312 United States


accepting new patients
Start Date
Completion Date
Regeneron Pharmaceuticals
A clinical study for adults and adolescents who are melanoma-free following surgery.
Phase 3 Skin Cancer/Melanoma Research Study
Study Type
Expecting 1530 study participants
Last Updated